Knight Therapeutics (KHTRF) announced that its Mexican affiliate, Grupo Biotoscana de Especialidad, received regulatory approval from COFEPRIS for TAVALISSE for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics price target lowered to C$7.50 from C$8 at Raymond James
- Knight Therapeutics price target lowered to C$6.25 from C$6.75 at Stifel
- Knight Therapeutics Reports Q3 2024 Financial Results
- Knight Therapeutics downgraded to Hold from Buy at Mackie Research Capital
- Knight Therapeutics reports Q3 EPS C$0.00 vs. C$0.09 last year